Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.94 USD
+0.04 (1.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPTX 3.94 +0.04(1.03%)
Will RPTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Other News for RPTX
Repare Therapeutics management to meet virtually with Piper Sandler
Buy Rating Affirmed for Repare Therapeutics on Promising Pipeline and Strategic Advantages
TD Cowen Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announces intial data from Phase 1 MINOTAUR trial